337 related articles for article (PubMed ID: 20553273)
1. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
[TBL] [Abstract][Full Text] [Related]
2. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
[TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
5. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
6. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
7. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
9. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
Funakoshi-Tago M
Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
[TBL] [Abstract][Full Text] [Related]
11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
12. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
13. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
14. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
Glück M; Dally L; Jücker M; Ehm P
Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
[TBL] [Abstract][Full Text] [Related]
15. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
[TBL] [Abstract][Full Text] [Related]
16. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic JAK2
Prestipino A; Emhardt AJ; Aumann K; O'Sullivan D; Gorantla SP; Duquesne S; Melchinger W; Braun L; Vuckovic S; Boerries M; Busch H; Halbach S; Pennisi S; Poggio T; Apostolova P; Veratti P; Hettich M; Niedermann G; Bartholomä M; Shoumariyeh K; Jutzi JS; Wehrle J; Dierks C; Becker H; Schmitt-Graeff A; Follo M; Pfeifer D; Rohr J; Fuchs S; Ehl S; Hartl FA; Minguet S; Miething C; Heidel FH; Kröger N; Triviai I; Brummer T; Finke J; Illert AL; Ruggiero E; Bonini C; Duyster J; Pahl HL; Lane SW; Hill GR; Blazar BR; von Bubnoff N; Pearce EL; Zeiser R
Sci Transl Med; 2018 Feb; 10(429):. PubMed ID: 29467301
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
19. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
[TBL] [Abstract][Full Text] [Related]
20. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.
Shide K; Shimoda K; Kamezaki K; Kakumitsu H; Kumano T; Numata A; Ishikawa F; Takenaka K; Yamamoto K; Matsuda T; Harada M
Leuk Res; 2007 Aug; 31(8):1077-84. PubMed ID: 17011030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]